NCT06066918 Prophylactic Pregabalin Treatment Following Spinal Cord Injury
| NCT ID | NCT06066918 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Loewenstein Hospital |
| Condition | Spinal Cord Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2021-07-13 |
| Primary Completion | 2026-02-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2021-07-13 with a primary completion date of 2026-02-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients arriving to rehabilitation up to 3 months following SCI will be given (study group) or not (control group) Lyrica (75X2). They will be followed for central pain development.
Eligibility Criteria
Inclusion Criteria: * Up to 3 months following traumatic or non-traumatic SCL * Ability to give informed consent and cooperate Exclusion Criteria: * Pregnancy * Neurological or other medical conditions that may interfere with sensation * Neuropathic-like pain before recruitment (described as painful sensation of electric current, burning, numbness, tingling, pricking, or squeezing) * Being treated with Pregabalin * Blood creatinine levels \>1.2 or creatinine clearance \<60 * Sensitivity to lactose
Contact & Investigator
Amiram Catz, Catz
PRINCIPAL INVESTIGATOR
Loewenstein Rehabilitation Hospital
Frequently Asked Questions
Who can join the NCT06066918 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06066918 currently recruiting?
Yes, NCT06066918 is actively recruiting participants. Contact the research team at amiramc@clalit.org.il for enrollment information.
Where is the NCT06066918 trial being conducted?
This trial is being conducted at Raanana, Israel.
Who is sponsoring the NCT06066918 clinical trial?
NCT06066918 is sponsored by Loewenstein Hospital. The principal investigator is Amiram Catz, Catz at Loewenstein Rehabilitation Hospital. The trial plans to enroll 50 participants.